FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC

On June 15, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lurbinectedin (Zepzelca, Pharma Mar S.A.) for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Read the FDA announcement.

Posted 6/16/2020